MedTrace Logo

A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin

NCT07331389 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2026-01-09

No results posted yet for this study

Summary

The purpose of this study is to characterize the drug-drug intereaction of HDM1002 and metformin, empagliflozin, midazolam, valsartan, and warfarin in overweight/obese adult subjects. The safety and tolerability of HDM1002 with metformin, empagliflozin, midazolam, valsartan, and warfarin when given separately or together will also be evaluated

Conditions

  • Overweight Subject
  • Healthy Subjects

Interventions

DRUG

Metformin

Administered orally

DRUG

Empagliflozin

Single dose; Administered orally

DRUG

Midazolam

Single dose; Administered orally

DRUG

Valsartan

Single dose; Administered orally

DRUG

Warfarin

Single dose; Administered orally

DRUG

HDM1002

Administered orally

Sponsors & Collaborators

  • Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-24
Primary Completion
2026-01-12
Completion
2026-06-13
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07331389 on ClinicalTrials.gov